Dr. Abbey Publishes Case Report on Macular Hole Closure with Intravitreal Dexamethasone Implant
In the September 2023 issue of the peer-reviewed medical journal Ophthalmic Surgery, Lasers and Imaging Retina, Texas Retina’s Ashkan Abbey, MD, describes the use of a dexamethasone intravitreal implant to close a
read more
New Clinical Trials Available at Texas Retina
Our physicians remain committed to participating in ongoing retina research, providing our patients with access to promising new treatments through clinical trials. In fact, our research program has grown to become one
read more Dr. Abbey Publishes Research on Effectiveness of a Long-acting Injectable Steroid for Patients with Cystoid Macular Edema After Vitrectomy
Long-acting injectable steroids have emerged as a new way to treat chronic intraocular inflammation and cystoid macular edema (CME) that reduces the treatment frequency and burden for retina patients. Texas Retina’s Ashkan
read more
Inflammatory Eye Disease Awareness Week
Prevent Blindness has declared September 18 – 24, 2023, as Inflammatory Eye Disease Awareness Week. There are a number of inflammatory eye conditions. The one we specialize in at Texas Retina Associates
read more Dr. Abbey Presented at the American Society of Retina Specialists 2023 Annual Meeting
Texas Retina Associates’ Ashkan M. Abbey, MD, recently presented at the 41st Annual Scientific Meeting of the American Society of Retina Specialists (ASRS) held in Seattle. ASRS is the largest organization of
read more
New Patient Portal System
Texas Retina Associates is in the process of transitioning to a new and improved patient portal system that will go live on Wednesday, August 9, 2023. This secure portal will provide you
read more
Texas Retina Associates First in U.S. to Dose a Patient in the Phase 2 SIGLEC Trial
On June 1, 2023, Ashkan Abbey, MD, dosed the first patient in the Phase II SIGLEC Trial, a clinical study evaluating AVD-104, a potential new treatment for geographic atrophy (GA) from age-related
read more
Dr. Abbey Presents Phase 1 DAVIO Clinical Trial Results to the Association for Research in Vision and Ophthalmology
Dr. Abbey presented the results from the Phase 1 DAVIO trial at ARVO 2023, the annual meeting of the Association for Research in Vision and Ophthalmology (ARVO). The trial was a first-in-human
read more Dr. Abbey Contributes to Real-world Study of Faricimab for Neovascular Age-related Macular Degeneration
The TRUCKEE study is a real-world, collaborative effort to investigate the efficacy, durability, and safety of a monoclonal antibody treatment called faricimab in patients suffering from neovascular age-related macular degeneration (nAMD) in
read more
Dr. Wang Participated in Roundtable Discussion on XIPERE Treatment for Macular Edema Associated with Uveitis
At the most recent American Academy of Ophthalmology (AAO) Annual Meeting in Chicago, Texas Retina Associates’ Robert Wang, MD, participated in a roundtable discussion with seven other retina specialists to share their
read more